EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ensol Biosciences's Enterprise Value is ₩74,876.1 Mil.
Ensol Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-8,206.0 Mil. Therefore, Ensol Biosciences's EV-to-FCF for today is -9.12.
The historical rank and industry rank for Ensol Biosciences's EV-to-FCF or its related term are showing as below:
XKRX:140610'
s EV-to-FCF Range Over the Past 10 Years
Min: -37.42 Med: -18.76 Max: -4.71
Current: -9.12
During the past 10 years, the highest EV-to-FCF of Ensol Biosciences was -4.71. The lowest was -37.42. And the median was -18.76.
XKRX:140610's EV-to-FCF is ranked worse than 100% of 384
companies
in the Biotechnology industry
Industry Median: 7.885
vs XKRX:140610: -9.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Ensol Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ensol Biosciences's EV-to-FCF
For the Biotechnology subindustry, Ensol Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensol Biosciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensol Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ensol Biosciences's EV-to-FCF falls into.
Ensol Biosciences's current Enterprise Value is ₩74,876.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ensol Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-8,206.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ensol Biosciences's PE Ratio for today is calculated as:
Ensol Biosciences's share price for today is ₩6540.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ensol Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-1054.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ensol Biosciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Ensol Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Ensol Biosciences (XKRX:140610) Business Description
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:140610 has been successfully added to your 